DISCOUNT ZERTIFIKAT - ASTRAZENECA ADR | Market Closed - Börse Stuttgart 11:51:18 25/06/2024 pm IST | ||
| 69.1 EUR | +0.38% |
|
| Current month | +3.06% | ||
| 1 month | +2.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 69.1 | +0.38% |
| 24/24/24 | 68.84 | -0.03% |
| 21/24/21 | 68.86 | +0.50% |
| 20/24/20 | 68.52 | +0.76% |
| 19/24/19 | 68 | -0.41% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 11:51 pm IST
More quotesStatic data
| Product type | Discount-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MG39PF |
| ISIN | DE000MG39PF2 |
| Date issued | 30/04/2024 |
| Maturity | 20/12/2024 (178 Days) |
| Parity | 1 : 1 |
| Emission price | 67.67 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 69.1 € |
|---|---|
| Lowest since issue | 66.16 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.68%
- Stock Market
- Certificates
- Certificat
